GTx Announces Departure of CEO

  GTx Announces Departure of CEO

  - Dr. Mitchell Steiner steps down as CEO and Vice Chairman of the Board -

         - Marc Hanover, GTx’s President and COO, named interim CEO -

Business Wire

MEMPHIS, Tenn. -- April 4, 2014

GTx, Inc. (NASDAQ: GTXI) today announced that Mitchell S. Steiner, its vice
chairman and chief executive officer (CEO) and a co-founder of the company, is
leaving GTx to pursue other business interests. Dr. Steiner has stepped down
from his roles as CEO and vice chairman of the Board of Directors at the
company effective Thursday April 3, 2014.

Marc S. Hanover, a co-founder of GTx, has been named interim CEO by the
Company’s Board. He also was elected by the Board to fill Dr. Steiner’s
remaining term as a Class II director, until the annual meeting of
shareholders in 2015. Mr. Hanover has served as president and chief operating
officer of GTx since the company’s inception in September 1997.

“Since co-founding the company, Mitch has played an instrumental role in
helping build GTx to develop novel medicines for cancer patients," said J.R.
Hyde, III, chairman of the Board of GTx. “The company remains committed to the
implementation of GTx’s strategy, which includes pursuing a marketing
application in Europe for enobosarm 3mg for the prevention and treatment of
muscle wasting in patients with advanced non-small cell lung cancer.”

“After more than 15 years as CEO, it’s a good time for me to leave my position
so that I can spend more time with my family and pursue different
opportunities,” said Dr. Steiner. “I remain excited by the company’s prospects
and the potential of GTx’s drug candidates to improve the lives of people
living with cancer.”

GTx remains focused on the following:

  *Completing the required Phase I studies and gaining regulatory approval of
    the company’s pediatric investigation plan (PIP) from the European
    Medicines Agency (EMA) Pediatric Committee in order to submit by the first
    quarter of 2015 a marketing authorization application (MAA) in the
    European Union (EU) for enobosarm 3mg for the prevention and treatment of
    muscle wasting in patients with advanced non-small cell lung cancer
    (NSCLC)
  *Completing in the 3^rd quarter of this year, the company’s ongoing Phase 2
    clinical study of enobosarm 9mg to treat androgen receptor and estrogen
    receptor positive advanced breast cancer
  *Meeting with the United States Food and Drug Administration (FDA) to
    determine an appropriate regulatory path forward in the U.S. for enobosarm
    3 mg for the prevention and treatment of cancer cachexia in NSCLC, and
  *Completing the company’s ongoing Phase 2 clinical study of GTx-758 as a
    secondary hormonal treatment for men with castration-resistant prostate
    cancer.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company
dedicated to the discovery, development, and commercialization of small
molecules for the treatment of cancer, cancer supportive care, including
prevention and treatment of cancer-related muscle wasting, and other serious
medical conditions.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's
current expectations. Forward-looking statements involve risks and
uncertainties, and include, but are not limited to, statements relating to the
anticipated completion of GTx's clinical trials for enobosarm (GTx-024) and
GTx-758 (Capesaris^®), the potential approval of GTx’s PIP from the EMA, the
potential submission of a MAA to the EMA for enobosarm 3mg and the timing
thereof, and GTx’s plans to meet with the FDA and a potential regulatory path
forward for enobosarm 3mg in the United States. GTx's actual results and the
timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties, which
include, without limitation, the risks (i) that GTx may be unable to
successfully complete or develop, in a timely manner or at all, the Phase 1
studies and PIP necessary to enable the submission of the planned MAA; (ii)
related to the uncertain and time-consuming regulatory approval process,
including the risk that GTx may not be able to obtain required regulatory
approvals to commercialize enobosarm 3mg in a timely manner or at all; (iii)
that clinical trials being conducted by GTx may not be completed on schedule,
or at all, or may otherwise be suspended or terminated or (iv) that GTx could
utilize its available cash resources sooner than it currently expects and may
be unable to raise additional capital, which would force GTx to delay, reduce
or eliminate its product candidate development programs. You should not place
undue reliance on these forward-looking statements, which apply only as of the
date of this press release. GTx’s annual report on Form 10-K filed with the
Securities and Exchange Commission on March 12, 2014 contains under the
heading, "Risk Factors", a more comprehensive description of these and other
risks to which GTx is subject. GTx expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.

Contact:

Media:
BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com
or
Investors:
GTx, Inc.
Marc Hanover, 901-507-6915
interim CEO, President and Chief Operating Officer
mhanover@gtxinc.com
 
Press spacebar to pause and continue. Press esc to stop.